Paroxysmal Nocturnal Hemoglobinuria

A case of paroxysmal nocturnal hemoglobinuria (PNH) is presented in which MR imaging and CT findings were characteristic. The signal intensity of renal cortex was lower than that of medulla on both T1- and T2-weighted imaging. On CT without contrast enhancement the attenuation of renal cortex was higher than that of renal medulla. These findings at MR imaging and CT were the results of a deposition of hemosiderin in the cells of proximal convoluted tubules, and were helpful for diagnosis of PNH.

• Publication year

  1991

• Venue

  Mayo Clinic proceedings

• Publication date

  1991-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/028418519103200410PMID 41171226
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria throughout clinical trials: from definition to clinical practice.

  2025cited by this paper
• Pathogenesis of Paroxysmal Nocturnal Hemoglobinuria.

  2025cited by this paper
• Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition

  2024cited by this paper
• Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria

  2024cited by this paper
• Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria

  2024cited by this paper
• Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.

  2024cited by this paper
• Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria

  2024cited by this paper
• A guide to complement biology, pathology and therapeutic opportunity

  2023cited by this paper
• Complement and platelets: prothrombotic cell activation requires membrane attack complex–induced release of danger signals

  2023cited by this paper
• Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial.

  2023cited by this paper
• Analysis of Costs per Responder in US Adults with Paroxysmal Nocturnal Hemoglobinuria with a Suboptimal Response to Prior Eculizumab Treatment

  2023cited by this paper
• Complement in human disease: approved and up-and-coming therapeutics.

  2023cited by this paper
• Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape.

  2023cited by this paper
• Complement biology for hematologists

  2023cited by this paper
• Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor‐naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single‐arm study

  2023cited by this paper
• Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition.

  2022cited by this paper
• How I Treat Paroxysmal nocturnal hemoglobinuria.

  2021cited by this paper
• Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.

  2021cited by this paper
• Is nature truly healing itself? Spontaneous remissions in Paroxysmal Nocturnal Hemoglobinuria

  2021cited by this paper
• The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK’s population‐based haematological malignancy research network 2004‐2018

  2021cited by this paper
• Paroxysmal Nocturnal Hemoglobinuria in the Context of a Myeloproliferative Neoplasm: A Case Report and Review of the Literature

  2021cited by this paper
• When does a PNH clone have clinical significance?

  2021cited by this paper
• Efficacy and Safety of Pegcetacoplan Treatment in Complement-Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Phase 3 Prince Study

  2021cited by this paper
• Chronic Budd-Chiari syndrome in paroxysmal nocturnal haemoglobinuria.

  2021cited by this paper
• Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry

  2020cited by this paper
• Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity.

  2020cited by this paper
• Paroxysmal nocturnal hemoglobinuria pnh

  2020cited by this paper
• Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria

  2020cited by this paper
• Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis

  2019cited by this paper
• Paroxysmal nocturnal hemoglobinuria without GPI-anchor deficiency.

  2019cited by this paper
• Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.

  2019cited by this paper
• A Phase III Study to Evaluate the Efficacy and Safety of APL-2 in Patients With PNH

  2019cited by this paper
• Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation.

  2019cited by this paper
• Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.

  2019cited by this paper
• Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.

  2017cited by this paper
• The prothrombotic state in paroxysmal nocturnal hemoglobinuria: a multifaceted source

  2017cited by this paper
• Paroxysmal nocturnal haemoglobinuria

  2017cited by this paper
• Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults.

  2017cited by this paper
• Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry

  2016cited by this paper
• Biosynthesis of GPI-anchored proteins: special emphasis on GPI lipid remodeling

  2016cited by this paper
• Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape

  2014cited by this paper
• Thrombosis in paroxysmal nocturnal hemoglobinuria.

  2013cited by this paper
• CCR 7-mediated LFA-1 functions in T cells are regulated by 2 independent ADAP / SKAP 55 modules

  2012cited by this paper
• Etsrp/Etv2 Is Directly Regulated by Foxc1a/b in the Zebrafish Angioblast

  2012cited by this paper
• Computational models of VEGF-associated angiogenic processes in cancer.

  2012cited by this paper
• Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria

  2012cited by this paper
• Protection Against Myocardial Infarction and No-Reflow Through Preservation of Vascular Integrity by Angiopoietin-Like 4

  2012cited by this paper
• MicroRNA-1 Regulates Smooth Muscle Cell Differentiation by Repressing Kruppel-Like Factor 4

  2011cited by this paper
• Vascular Dementia

  2011cited by this paper
• Developmental timing of CCM2 loss influences cerebral cavernous malformations in mice

  2011cited by this paper
• Quantifying the role of angiogenesis in malignant progression of gliomas: in silico modeling integrates imaging and histology.

  2011cited by this paper
• Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial.

  2011cited by this paper
• Targeted inhibition of complement activation prevents features of preeclampsia in mice.

  2011cited by this paper
• Epigenetic regulation of pulmonary arterial hypertension

  2011cited by this paper
• Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now.

  2011cited by this paper
• Nonmuscle Myosin Light-Chain Kinase Deficiency Attenuates Atherosclerosis in Apolipoprotein E–Deficient Mice via Reduced Endothelial Barrier Dysfunction and Monocyte Migration

  2011cited by this paper
• Fetal programming of pulmonary vascular dysfunction in mice: role of epigenetic mechanisms.

  2011cited by this paper
• Regulation of ocular angiogenesis by Notch signaling: implications in neovascular age-related macular degeneration.

  2011cited by this paper
• Management of erectile dysfunction in patients with sickle cell disease.

  2011cited by this paper
• Myoendothelial gap junctional signaling induces differentiation of pulmonary arterial smooth muscle cells.

  2011cited by this paper
• Regulation of the lymphatic endothelial cell cycle by the PROX1 homeodomain protein.

  2011cited by this paper
• The Er71 Is an Important Regulator of Hematopoietic Stem Cells in Adult Mice

  2011cited by this paper
• Heme Oxygenase in the Regulation of Vascular Biology: From Molecular Mechanisms to Therapeutic Opportunities

  2011cited by this paper
• Intermedin induces loss of coronary microvascular endothelial barrier via derangement of actin cytoskeleton: role of RhoA and Rac1.

  2011cited by this paper
• Tumorigenic Development of Induced Pluripotent Stem Cells in Ischemic Mouse Brain

  2011cited by this paper
• Controlled activation of morphogenesis to generate a functional human microvasculature in a synthetic matrix.

  2011cited by this paper
• Local kinetics of morphogen gradients

  2011cited by this paper
• Epigenetically coordinated GATA2 binding is necessary for endothelium‐specific endomucin expression

  2011cited by this paper
• miR-143 and miR-145: molecular keys to switch the phenotype of vascular smooth muscle cells.

  2011cited by this paper
• Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E–deficient mice

  2011cited by this paper
• Computational Modeling of Interacting VEGF and Soluble VEGF Receptor Concentration Gradients

  2011cited by this paper
• Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice.

  2011cited by this paper
• Pain management of children and adolescents with sickle cell disease presenting to the emergency department.

  2011cited by this paper
• Conditional deletion of Dicer in vascular smooth muscle cells leads to the developmental delay and embryonic mortality.

  2011cited by this paper
• Increased expression of matrix metalloproteinase-1 in systemic vessels of preeclamptic women: a critical mediator of vascular dysfunction.

  2011cited by this paper
• Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena

  2011cited by this paper
• Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML

  2011cited by this paper
• CD63 is an essential cofactor to leukocyte recruitment by endothelial P-selectin.

  2011cited by this paper
• Regulation of human neutrophil Fcγ receptor IIa by C5a receptor promotes inflammatory arthritis in mice.

  2011cited by this paper
• Specificity Protein-1 as a Critical Regulator of Human Cystathionine γ-Lyase in Smooth Muscle Cells*

  2011cited by this paper
• Dissociation of VE-PTP from VE-cadherin is required for leukocyte extravasation and for VEGF-induced vascular permeability in vivo

  2011cited by this paper
• Insights Into Coronary Artery Development in Model of Maternal Protein Restriction in Mice

  2011cited by this paper
• Effect of red wine on adipocytokine expression and vascular alterations in fructose-fed rats.

  2011cited by this paper
• Irbesartan inhibits advanced glycation end product (AGE)-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular endothelial cells.

  2011cited by this paper
• Vascular endothelial growth factor protects post‐ganglionic sympathetic neurones from the detrimental effects of hydrogen peroxide by increasing catalase

  2011cited by this paper
• Endothelial nitric oxide synthase overexpression restores the efficiency of bone marrow mononuclear cell-based therapy.

  2011cited by this paper
• Reversible acute kidney injury caused by paroxysmal nocturnal hemoglobinuria.

  2011cited by this paper
• The serotonin transporter, gender, and 17β oestradiol in the development of pulmonary arterial hypertension.

  2011cited by this paper
• The Transcription Factor E74-Like Factor Controls Quiescence of Endothelial Cells and Their Resistance to Myeloablative Treatments in Bone Marrow

  2011cited by this paper
• Can microRNAs control vascular smooth muscle phenotypic modulation and the response to injury?

  2011cited by this paper
• Molecular control of endothelial cell behaviour during blood vessel morphogenesis

  2011cited by this paper
• Thrombosis in patients with paroxysmal nocturnal hemoglobinuria.

  2011cited by this paper
• Mitogen-activated protein kinase phosphatase-1 is a key regulator of hypoxia-induced vascular endothelial growth factor expression and vessel density in lung.

  2011cited by this paper
• Regulation of MMP10 expression by the transcription factor CHF1/Hey2 is mediated by multiple E boxes.

  2011cited by this paper
• Differential expression of the bone and the liver tissue non-specific alkaline phosphatase isoforms in brain tissues

  2011cited by this paper
• BASIC AND TRANSLATIONAL — ALIMENTARY TRACT Serum Response Factor – Dependent MicroRNAs Regulate Gastrointestinal Smooth Muscle Cell Phenotypes

  2011cited by this paper
• Prediction of onset and course of high hospital utilization in sickle cell disease.

  2011cited by this paper
• Cardiopulmonary bypass in a patient with classic paroxysmal nocturnal hemoglobinuria during treatment with eculizumab

  2011cited by this paper
• Role of Perivascular Adipose Tissue–Derived Methyl Palmitate in Vascular Tone Regulation and Pathogenesis of Hypertension

  2011cited by this paper
• Declining Stroke and Vascular Event Recurrence Rates in Secondary Prevention Trials Over the Past 50 Years and Consequences for Current Trial Design

  2011cited by this paper

• Hemolytic Rebound and Recurrent Thromboembolic Event Following Ravulizumab Discontinuation in a Patient with PNH and MDS: A Case Report

  2026cites this paper
• Paroxysmal Nocturnal Hemoglobinuria as a Rare Cause of Chronic Asymptomatic Hemolysis: A Case Report

  2026cites this paper
• Comparative Efficacy of Complement Inhibitors in Complement Inhibitor–Naïve PNH: A Systematic Review With Supportive Exploratory Network Meta‐Analysis of Randomized Trials

  2026cites this paper
• Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria

  2025cites this paper
• Advances in Complement Inhibition Therapies for Paroxysmal Nocturnal Hemoglobinuria and Autoimmune Hemolytic Disorders

  2025influential citation
• Effect of Target‐Mediated Disposition on Iptacopan Clinical Pharmacokinetics in Participants with Normal or Impaired Hepatic Function

  2025cites this paper
• Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations

  2025cites this paper
• Description of 18 PNH patients with prevalent GPI‐deficient monocytes. An Italian survey

  2025cites this paper
• Paroxysmal Nocturnal Hemoglobinuria: Unraveling Its Molecular Pathogenesis and Advancing Targeted Therapeutic Strategies

  2025influential citation
• Factor B as a therapeutic target for the treatment of complement-mediated diseases

  2025cites this paper
• The Advancing Landscape of Paroxysmal Nocturnal Hemoglobinuria Treatment

  2025influential citation
• Disease Activity After Switching From Eculizumab to Ravulizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria: Real World Data From Denmark and Finland

  2025cites this paper
• Model-Informed Precision Dosing of Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria

  2025cites this paper
• Repair of Congenital Cardiac Disease Requiring Bypass for a Pediatric Patient With Paroxysmal Nocturnal Hemoglobinuria

  2025cites this paper
• Pharmacokinetic characterization and exposure–response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria

  2025cites this paper
• Striving for excellence in paroxysmal nocturnal hemoglobinuria in Canada: the EPIC program

  2025cites this paper
• Paroxysmal nocturnal hemoglobinuria presenting with acute kidney injury in an 18-year-old male: a case report.

  2025cites this paper
• Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria

  2024cites this paper
• Single‐cell sequencing reveals alterations in the differentiation of bone marrow haematopoietic cells in patients with paroxysmal nocturnal haemoglobinuria

  2024cites this paper
• Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria

  2024cites this paper
• Crovalimab: a new era in paroxysmal nocturnal hemoglobinuria management

  2024cites this paper
• Advancements in PNH treatment: crovalimab’s clinical efficacy

  2024cites this paper
• Comparative study of the diversity of amino acids on human leucocyte antigen class II molecules in patients with acquired aplastic anaemia

  2024cites this paper
• Novel treatment of Paroxysmal Nocturnal Haemoglobinuria with wheat grass oral therapy

  2024cites this paper
• A Retrospective Claims Analysis of the Rate of Complications in Patients Undergoing Treatment for Paroxysmal Nocturnal Hemoglobinuria

  2024cites this paper
• Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria

  2024cites this paper
• Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria.

  2024cites this paper
• The complement model disease paroxysmal nocturnal hemoglobinuria

  2024cites this paper
• Case report on "Spontaneous Remission in Paroxysmal Nocturnal Hemoglobinuria: A Rare Phenomenon

  2024cites this paper
• Management of paroxysmal nocturnal hemoglobinuria in CALR mutated post‐essential thrombocythemia myelofibrosis: A case report

  2024cites this paper
• Urine complement proteins are associated with kidney disease progression of type 2 diabetes in Korean and American cohorts

  2024cites this paper
• Recent advances in cell membrane camouflaged nanotherapeutics for the treatment of bacterial infection

  2024cites this paper
• Uncovering the Challenges of Rare Diseases: Insights From a Retrospective Cross-Sectional Study in Albania (2005-2022)

  2024cites this paper
• Complement in immune thrombocytopenia (ITP): The role of complement in refractory ITP

  2023cites this paper
• Haemolytic paroxysmal nocturnal haemoglobinuria in patients with myeloid neoplasms: A rare association with specific therapeutic implications

  2023cites this paper
• Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison

  2023cites this paper
• Prognostic value of pre-treatment PNH clone among the patients with aplastic anemia: a meta-analysis

  2023cites this paper
• Paroxysmal Nocturnal Hemoglobinuria: Biology and Treatment

  2023cites this paper
• Long noncoding RNA FAM157C contributes to clonal proliferation in paroxysmal nocturnal hemoglobinuria

  2023cites this paper
• Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands

  2023cites this paper
• The Many Faces of Hemolysis

  2023cites this paper
• Candida krusei pneumonia in graft-versus-host disease after allogeneic hematopoietic stem cell transplant for paroxysmal nocturnal hemoglobinuria: a case report

  2023cites this paper
• Interventions in cerebrovascular emergencies among patients with Paroxysmal nocturnal haemoglobinuria - A word of caution.

  2023cites this paper
• Unraveling the Connection: PNH Induced Budd-Chiari Syndrome - A Case Study and Early Detection Emphasis

  2023cites this paper
• Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape.

  2023cites this paper
• Eculizumab for paroxysmal nocturnal haemoglobinuria: catastrophic health expenditure in Nepalese patients

  2023cites this paper
• Pancitopenia como apresentação inicial de anemia perniciosa: relato de caso de uma abordagem minimamente invasiva

  2023cites this paper
• The disease burden of paroxysmal nocturnal hemoglobinuria in Denmark: Epidemiology, survival, healthcare resource utilization, costs, treatment gaps, and labor market attachment

  2023cites this paper
• The Features of COVID-19’s Course and the Efficacy of the Gam-COVID-Vac Vaccine in Patients with Paroxysmal Nocturnal Hemoglobinuria

  2023cites this paper
• COVID-19 vaccination prevents a more severe course and treatment with complement inhibitors reduce worsening hemolysis during the Omicron pandemic in patients with PNH: a single-center study

  2023cites this paper
• The Effect of Respiratory Viral Infections on Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria

  2023cites this paper
• Central Retinal Vein Occlusion Secondary to Paroxysmal Nocturnal Hemoglobinuria

  2022cites this paper
• Eculizumab's Unintentional Mayhem: A Systematic Review

  2022cites this paper
• The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient‐reported insights on symptoms and quality of life

  2022cites this paper
• Pregnancy outcome of women with Paroxysmal Nocturnal Hemoglobinuria

  2022cites this paper
• Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies

  2022cites this paper
• Non-diseased aortic mural thrombus presenting with acute limb ischaemia

  2022cites this paper
• Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real‐world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry

  2022influential citation
• Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria

  2022cites this paper
• CD157 Can Replace CD24 and CD14 in a Single-Tube Flow-Cytometric Assay to Detect Paroxysmal Nocturnal Hemoglobinuria (PNH) Clones on Both Neutrophils and Monocytes: A Prospective Study From North India

  2022cites this paper
• Primary myelofibrosis with concurrent paroxysmal nocturnal haemoglobinuria presenting with erectile dysfunction

  2022influential citation
• The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target

  2022cites this paper
• Successful management of unstable angina in a ravulizumab-treated patient with paroxysmal nocturnal hemoglobinuria

  2022cites this paper
• Composite endpoint to evaluate complement inhibition therapy in patients with paroxysmal nocturnal hemoglobinuria

  2022cites this paper
• Pitfalls in complement analysis: A systematic literature review of assessing complement activation

  2022cites this paper
• Gata1s mutant mice display persistent defects in the erythroid lineage

  2022cites this paper
• Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan

  2022cites this paper
• Occurrence of a paroxysmal nocturnal hemoglobinuria clone in an essential thrombocythemia: a link between PIGV and MPL

  2022cites this paper
• The Effect of Sample Glucose Content on PNGase F-Mediated N-Glycan Release Analyzed by Capillary Electrophoresis

  2022cites this paper
• Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications

  2022cites this paper
• Pancytopenia in a Case of Aplastic Anaemia/Paroxysmal Nocturnal Haemoglobinuria Unmasked by SARS-CoV-2 Infection: A Case Report

  2022cites this paper
• Clinical characteristics of 512 eculizumab-naive paroxysmal nocturnal hemoglobinuria patients in China: a single-center observational study

  2022cites this paper
• Classical Paroxysmal Nocturnal Hemoglobinuria Presenting With Severe Anemia and Pigmented Acute Kidney Injury

  2022influential citation
• A Pig-a conditional knock-out mice model mediated by Vav-iCre: stable GPI-deficient and mild hemolysis

  2022cites this paper
• Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs.

  2022cites this paper
• Paroxysmal nocturnal haemoglobinuria, diagnosis and haematological findings, first report from Iran, model for developing countries

  2022cites this paper
• Biosimilars in rare diseases : a focus on paroxysmal nocturnal hemoglobinuria

  2022cites this paper
• History, Etiology, and Treatment of Paroxysmal Nocturnal Hemoglobinuria

  2022influential citation
• Whole blood transfusion and paroxysmal nocturnal haemoglobinuria meet again: Minor incompatibility, major trouble

  2022cites this paper
• Complement as a Therapeutic Target in Systemic Autoimmune Diseases

  2021cites this paper
• A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm

  2021cites this paper
• Long Non-Coding RNA FAM157C Contributed to Clonal Proliferation in Paroxysmal Nocturnal Hemoglobinuria

  2021cites this paper
• Centennial development of paroxysmal nocturnal hemoglobinuria research in Peking Union Medical College Hospital

  2021cites this paper
• Profiling plasma‐extracellular vesicle proteins and microRNAs in diabetes onset in middle‐aged male participants in the ELSA‐Brasil study

  2021cites this paper
• How we(’ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future

  2021cites this paper
• Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab

  2021cites this paper
• JAK2V617F positive polycythemia vera with paroxysmal nocturnal hemoglobinuria and visceral thromboses: a case report and review of the literature

  2021cites this paper
• Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores

  2021cites this paper
• No impact of Asian ethnicity on EORTC QLQ-C30 scores: Group differences and differential item functioning in paroxysmal nocturnal hemoglobinuria

  2021cites this paper
• MRI as a Aiagnostic Tool for Paroxysmal Nocturnal Hemoglobinuria: A Case Report

  2021cites this paper
• Coronary Artery By-Pass Grafting in Patient With Paroxysmal Nocturnal Hemoglobinuria (Case Report)

  2021cites this paper
• Advances in the creation of animal models of paroxysmal nocturnal hemoglobinuria

  2021cites this paper
• APLASTIC ANEMIA ASSOCIATED WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

  2021cites this paper
• Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria

  2021cites this paper
• Hematopoietic Stem Cell Transplantation for Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Aplastic Anemia: A Multicenter Turkish Experience

  2021cites this paper
• Concept confirmation of the Treatment Administration Satisfaction Questionnaire (TASQ) in rare paroxysmal nocturnal hemoglobinuria

  2021cites this paper
• Lactate dehydrogenase versus haemoglobin: which one is the better marker in paroxysmal nocturnal haemoglobinuria?

  2021cites this paper
• The Role of T Lymphocytes in the Pathogenesis of Paroxysmal Nocturnal Hemoglobinuria

  2021cites this paper
• Complement-related thrombosis

  2021cites this paper
• Constitutional PIGA mutations cause a novel subtype of hemochromatosis in patients with neurologic dysfunction

  2021cites this paper